

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
If the point of a healthcare system is to provide people with the healthcare they need, the Republican proposals are nonstarters.
During his first term, after repeatedly promising the country a terrific healthcare plan, Donald Trump famously commented, “Nobody knew that healthcare could be so complicated.” In fact, everyone who spent even a few minutes looking at the issue knew that healthcare was complicated. That is why Obamacare ended up being a hodgepodge that was pasted together to extend healthcare coverage as widely as possible. It is also the reason Trump and the Republicans never produced a healthcare plan in Trump’s first term.
The basic problem is that healthcare costs are hugely skewed. Ten percent of the population accounts for more than 60% of total spending, and just 1% accounts for 20% of spending. Most people have relatively low healthcare costs. The trick with healthcare is paying for small number of people who do have high costs.
The Republicans in Congress, along with Trump on alternate days, are pushing plans that are supposed to give choice to individuals and somehow take it away from insurers. It’s not clear what they think they are saying. They seem to still envision that people will buy insurance, as they do now in the Obamacare exchanges, but somehow that they will have more control in the Republican option.
There is one story they could envision, which would make it much easier for insurers to skew their pool. The Affordable Care Act (ACA) restricted what sort of plans could be offered in the exchanges in order to limit the ability for insurers to avoid high-cost individuals.
It would be possible to relax these restrictions to allow insurers to cherry pick their enrollees. For example, they could offer high-deductible plans, say $15,000 in payments, before any coverage kicked in.
The Republican healthcare plan is a rerun of the bluff and lie strategy they have been doing for more than 15 years.
No person with a serious health condition would buy this sort of plan since they know they would be paying at least $15,000 a year in medical expenses, and then a substantial fraction of everything above this amount, in addition to the premium itself. On the other hand, a low-cost plan with $15,000 deductible might look pretty good to someone in good health, whose medical expenses usually don’t run beyond the cost of annual checkup.
The Republicans can look like the great promoters of individual choice by allowing insurers to market these high-deductible plans. The problem is that healthy people will all gravitate to high-deductible plans, leaving only the people with serious health issues—the 10%—to buy plans with more modest deductibles.
These plans will then be ridiculously expensive since insurers are not going to insure people at a loss. If they have a pool with four or five times the average per person healthcare costs, they will charge a premium that is four five times the average cost, plus a margin for administrative costs and profits. This means that cancer survivors, people with heart disease, and other serious health conditions will be screwed, given the option of ridiculously expensive insurance or none at all.
The most painful part of this story is that we have all been around the block many times on this story. Unless Trump and the Republicans are extremely ignorant, which can never be ruled out, they are simply lying and hope that the media will let them get away with it. They have no brilliant plan to lower healthcare costs. They are simply proposing a scheme that will lower premiums for healthy people by screwing the ones who need healthcare most.
It amounts to lowering costs by not providing care. It’s like reducing the cost of food by not letting people eat. But if the point of a healthcare system is to provide people with the healthcare they need, the Republican proposals are nonstarters.
As a practical matter, contrary to what the Republicans and the media say, healthcare cost growth did slow sharply after Obamacare passed. That may not have been entirely due to Obamacare, but that is the reality. Too bad the Democratic consultants tell Democratic politicians not to talk about it.
We do pay way too much for healthcare in the United States, but it is not because of Obamacare. We pay twice as much for our drugs, medical equipment, and doctors as people in other wealthy countries. These high payments persist because they are supported by powerful lobbies.
Some of us had hope that the Trump administration might take some steps to reduce these prices, especially in the case of drugs, since RFK, Jr. had railed against corruption in the pharmaceutical industry. Unfortunately, his tirades were limited to an evidence-free crusade against long-proven vaccines, which are not even a major source of profit for the industry.
Donald Trump talked about reducing drug prices 1,500% (really), but this mostly amounted to getting his name on a drug discount website for a small group of patients. We were spending 6.4% more on drugs in September of this year than in the same month in 2024. (September is the most recent month for which data are available.)
Trump has shown no interest in doing anything to lower the cost of medical equipment. And he has said nothing about lowering doctors’ fees, although some reshuffling of the Medicare reimbursement schedules may reduce overpayments to specialists and better pay for family practitioners. His immigration policies are going the wrong way here, making it even more difficult for foreign-trained medical students and doctors to practice here.
And there are the insurers themselves, which gobble up close to 25% of the money they pay out to providers in the form of administrative costs and profits. A recent study found that If we add in the cost imposed by insurers on hospitals, doctors’ offices, and other providers, they take up close to a third of healthcare expenses.
Trump has shown no interest in reining in the insurance industry apart from his silly talking point about giving people money directly to… wait, wait, buy their own unregulated insurance. That will do nothing to reduce the money flowing into the industry’s pockets.
The Republican healthcare plan is a rerun of the bluff and lie strategy they have been doing for more than 15 years. Given the right-wing control of much of the media, it could work for them politically. The tragic part of the story is that millions could end up without the healthcare they need.
One British lawmaker condemned the agreement as "a Trump shakedown of the NHS."
The government of British Prime Minister Keir Starmer faced swift backlash on Monday after the Trump administration announced a deal under which the United Kingdom's prized National Health Service would pay higher prices for new medicines in exchange for tariff exemptions.
The agreement in principle, outlined in a statement by the Office of the United States Trade Representative, was seen by UK lawmakers and advocacy groups as a gross capitulation to US President Donald Trump and the pharmaceutical industry that would harm the NHS and British patients for years to come.
"Giving in to Big Pharma’s demands to hike the price of medicines spells disaster for our NHS, and for the lives of ordinary people," said Global Justice Now, a UK-based group. "We are being held to ransom. Our government must stand up to Big Pharma and for our NHS by reversing course."
Under the three-year deal, the NHS would boost the net price it pays for new pharmaceutical drugs, many of which emerge from the US, by 25%—a change that's expected to cost British taxpayers roughly £3 billion. In return, Trump has agreed not to impose tariffs on UK pharmaceuticals.
Helen Morgan, the Liberal Democrat MP for North Shropshire, denounced the new agreement as "a Trump shakedown of the NHS." As evidence, she pointed to US Health and Human Services Secretary Robert F. Kennedy Jr.'s celebration of the bilateral deal.
"It cannot go ahead," said Morgan. "RFK Jr. has put it in black and white: Trump demanded these pay rises to put Americans first, and our government rolled over. Patients stuck on crammed hospital corridors, or unable to get an ambulance, won’t forget it."
"The British people didn’t vote for this," Morgan added. "The government must put this agreement to a vote in parliament.”
Andrew Hill, a visiting health economics researcher at the University of Liverpool, similarly criticized the deal.
“The UK hasn’t benefited from this at all, but we’re having to pay all this extra money," said Hill. "More money spent on drugs means less money spent on ambulances, doctors, nurses, simple health interventions."
In addition to facing the threat of Trump tariffs, the UK government was under pressure from the powerful pharmaceutical industry to jack up NHS drug spending. The Guardian reported in September that "big pharmaceutical companies have ditched or paused nearly £2 billion in planned UK investments so far this year" as the firms "accused the government of not spending enough on new medicines."
Survey data released just ahead of Monday's deal announcement shows that 64% of the British public is opposed to the NHS paying higher prices for medicines.
"This is a betrayal of NHS patients," said Diarmaid McDonald, executive director of the advocacy group Just Treatment. "Big Pharma have got what they want. Donald Trump has got what he wants. In the face of their coordinated threats, the government has folded and thousands of patients will pay for this with their lives, as precious funds get stripped from other parts of the health service to line the pockets of rich pharmaceutical execs."
"MPs need to urgently hold the government to account," McDonald added, "and demand they publish the evidence showing the impact of this catastrophic move.”
"This outrageous giveaway to Big Pharma does nothing to lower prices in the United States. It only hurts UK patients."
Asked at a Monday press briefing if the deal would actually benefit US patients and consumers, as the Trump administration has claimed, or if the alleged revenue generated by the agreement would just be "sucked up" by the drug companies, White House Press Secretary Karoline Leavitt did not have an immediate answer.
"I'm going to be honest with you, Ed," Leavitt told the reporter: "I'll get you an answer to that question after the briefing."
Peter Maybarduk, Public Citizen’s Access to Medicines director, argued in a statement that the agreement wouldn't help Americans or Britons.
" Drug prices are far too high everywhere, including in the UK, backed by patent monopolies and contributing to rationing and preventable suffering," said Maybarduk. "This outrageous giveaway to Big Pharma does nothing to lower prices in the United States. It only hurts UK patients while distracting from the serious action needed at home to hold Pharma accountable and make medicine affordable and available for all.”
"Medicare drug price negotiation is about to deliver tangible lower costs to seniors in Medicare, unlike Trump’s ceremonial events with Big Pharma CEOs in the Oval Office," said one Democratic senator.
The Trump administration on Tuesday announced newly negotiated prices for more than a dozen prescription drugs covered by Medicare, an achievement made possible by a Biden-era law that has faced relentless attacks from the pharmaceutical industry, GOP lawmakers, and the Republican president.
The announcement marks the end of the second round of Medicare drug price negotiations required under the Inflation Reduction Act (IRA), a measure passed in 2022 without the support of a single Republican in Congress. Last year, House GOP leaders said the law was "disastrous" and decried what they called "the mandate from bureaucrats to artificially set prescription drug prices."
The new list contains 15 drugs, including the diabetes and weight loss medication Ozempic, the breast cancer drug Ibrance, and the prostate cancer drug Xtandi. The Centers for Medicare & Medicaid Services (CMS) estimated that if the new prices—which take effect in 2027—had been in effect last year, Medicare would have saved $12 billion.
President Donald Trump campaigned on rolling back the IRA, which for the first time allowed Medicare to negotiate drug prices directly with pharmaceutical companies. Since taking office, Trump has taken steps to weaken the law, including by signing a measure that will exempt certain high-priced drugs from Medicare negotiations—a multibillion-dollar handout to Big Pharma.
But in statements on Tuesday, Trump-appointed officials hailed the newly negotiated prices. Robert F. Kennedy Jr., secretary of the Health and Human Services Department, said the negotiation results stemmed from a Trump directive to "stop at nothing to lower healthcare costs for the American people."
CMS Administrator Mehmet Oz declared that the second round of negotiations was more successful than the first, which was held under the Biden administration. Experts said that claim is specious at best.
Democratic lawmakers were quick to highlight Republican opposition to the IRA, and continued attacks on the law, in response to the newly negotiated prices.
"Democrats took on Big Pharma by giving Medicare the power to negotiate on behalf of the tens of millions of seniors that want lower drug prices while every Republican voted against it,” said Sen. Ron Wyden (D-Ore.), the top Democrat on the Senate Finance Committee. “Today’s announcement is a result of that effort by Democrats to lower health costs for older Americans."
"Medicare drug price negotiation is about to deliver tangible lower costs to seniors in Medicare, unlike Trump’s ceremonial events with Big Pharma CEOs in the Oval Office," Wyden added. "Republicans neutered future Medicare drug price negotiations by adding delays and exemptions to some of the most expensive drugs, especially cancer drugs like Keytruda."
Tuesday's announcement came less than a week after the pharmaceutical industry suffered its 16th defeat in court as it continues its legal campaign against the Medicare price negotiations. The industry is also lobbying aggressively in support of legislation that would further weaken the IRA price-negotiation provisions.
"Drug corporations already secured a $9 billion giveaway from President Trump and congressional Republicans paid for by taxpayers and cancer patients through the Big Ugly Bill, and they are trying to go even further to delay and exempt price negotiations for more blockbuster drugs," said Steve Knievel, access to medicines advocate at Public Citizen.
"Policymakers must reject these efforts to undermine Medicare drug price negotiations," Knievel added. "Instead they should build on the program’s success by providing everyone access to negotiated prices, negotiating lower prices for more drugs sooner, and ensuring drug corporations can no longer rip us off by charging the highest prices in the world for medications."